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Within the phospholipase A2 (PLA2) superfamily that hydrolyzes phospholipids to yield fatty acids and
lysophospholipids, the secreted PLA2 (sPLA2) enzymes comprise the largest family that contains 11 isoforms in
mammals. Individual sPLA2s exhibit unique distributions and specific enzymatic properties, suggesting their distinct
biological roles. While sPLA2s have long been implicated in inflammation and atherosclerosis, it has become
evident that they are involved in diverse biological events through lipid mediator-dependent or
mediator-independent processes in a given microenvironment. In recent years, new biological aspects of sPLA2s
have been revealed using their transgenic and knockout mouse models in combination with mass spectrometric
lipidomics to unveil their target substrates and products in vivo. In this review, we summarize our current
knowledge of the roles of sPLA2s in metabolic disorders including obesity, hepatic steatosis, diabetes, insulin
resistance, and adipose tissue inflammation.
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Phospholipase A2 (PLA2) is a group of enzymes that
hydrolyze phospholipids to yield fatty acids and lysopho-
spholipids (Fig. 1). In general, this reaction is best known as
the initial, rate-limiting step of arachidonate metabolism
leading to the production of bioactive lipid mediators in-
cluding prostaglandins and leukotrienes. The mammalian
genome encodes more than 30 PLA2s or related enzymes,
among which the secreted phospholipase A2 (sPLA2) family
consists of low molecular mass and Ca2+-requiring en-
zymes with a conserved His-Asp catalytic dyad and in-
cludes 11 isoforms (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA,
and XIIB) [1–5]. Beyond cytosolic PLA2 (cPLA2α; group
IVA PLA2) whose regulatory roles in arachidonate metabol-
ism have been well documented [6], the biological roles of
sPLA2s remained a mystery for more than two decades.
Recent studies using mice that have been gene manipulated
for sPLA2s have begun to reveal their distinct and unique
roles in various biological events [7–14]. The current un-
derstanding of the in vivo functions of sPLA2s has been
summarized in several reviews [1–5].* Correspondence: murakami-mk@igakuken.or.jp
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flammation and atherosclerosis. This idea stems from the
observations that sPLA2-IIA, a prototypic “inflammatory
sPLA2,” is induced during inflammation [15] and that hy-
drolysis of low-density lipoprotein (LDL) by sPLA2s gives
rise to pro-atherogenic LDL, which promotes macrophage
foam cell formation in vitro [16, 17]. Indeed, subsequent
genetic and pharmacological approaches support the pro-
inflammatory or atherosclerotic roles of sPLA2s [10–14].
However, the regulatory roles of sPLA2s in metabolic dis-
orders including obesity and insulin resistance have not
yet been fully elucidated. Recently, it has become clear that
several sPLA2s are expressed in the adipose tissue or
gastrointestinal (GI) tract and have variable influences on
systemic metabolic states [18–20]. Here, we will make an
overview of the novel biological roles of sPLA2s and the
lipid pathways underlying metabolic regulation, as revealed
by sophisticated knockout and lipidomics techniques.sPLA2-V, a “metabolic sPLA2”
Metabolic syndrome is increasing at an explosive rate
worldwide due to a pandemic of obesity associated with
diabetes, insulin resistance, non-alcoholic fatty liver dis-
ease, and hyperlipidemia [21]. The mechanisms connect-
ing obesity to insulin resistance include an elevated leveldistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 PLA2 reaction. PLA2 hydrolyzes the sn-2 position of glycerophospholipids to yield fatty acids (typically unsaturated) and lysophospholipids.
Phospholipases A1, C, and D (PLA1, PLC, and PLD, respectively) cleave other ester bonds in the glycerophospholipid molecule. Unsaturated fatty
acids and lysophospholipids are further metabolized to a variety of lipid mediators
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lipotoxicity, and chronic inflammation in metabolically
active tissues [22]. Obesity arises through the dysregula-
tions of intracellular lipid metabolism or extracellular
lipid partitioning among tissues, and the perturbation of
intracellular/extracellular lipases variably and often pro-
foundly affect obesity and insulin resistance [23–26]. For
instance, lipoprotein lipase is an obesity susceptibility
factor showing an inverse relationship between its activ-
ity and obesity-related traits in humans [23]. The imbal-
anced accumulation of LDL in favor of high-density
lipoprotein (HDL) is a critical risk factor not only for
atherosclerosis but also for insulin intolerance [27]. As
lipoprotein particles are shielded by phospholipids,
aberrant lipoprotein phospholipid metabolism could also
influence lipid partitioning and thereby obesity.
Among the sPLA2 isoforms, sPLA2-V potently hydrolyzes
phospholipids in lipoproteins (LDL > HDL) in vitro [17].
However, studies using Pla2g5−/− mice have failed to dem-
onstrate the participation of sPLA2-V in LDL metabolism
in atherosclerosis models [11, 28]. Except for studies using
sPLA2-overexpressing transgenic mice [17, 29, 30], no re-
ports have firmly established whether endogenous sPLA2s
affect lipoprotein metabolism in vivo. In a microarray
search for unique lipase-related genes whose expressions
are associated with obesity, we recently found that sPLA2-V
(and sPLA2-IIE; see below) is robustly induced in adipo-
cytes of obese mice [18]. This sPLA2-V induction is
dependent on adipogenesis plus endoplasmic reticulum
(ER) stress. Because of this property plus the fact that
sPLA2-V is constitutively expressed at relatively high levels
in several metabolic tissues such as the heart and skeletal
muscle, we refer to sPLA2-V as a “metabolic sPLA2.”Notably, when fed a high-fat diet (HFD), Pla2g5−/− mice
display hyperlipidemia with higher plasma levels of LDL,
increased obesity and hepatic steatosis, and lower insu-
lin sensitivity [18]. Furthermore, the adipose tissues in
Pla2g5−/− mice show a greater infiltration of M1 macro-
phages and a higher expression of pro-inflammatory
cytokines. Thus, sPLA2-V plays anti-obesity and anti-
inflammatory roles in the context of metabolic disor-
ders. Lipidomics have revealed that sPLA2-V secreted
from hypertrophic adipocytes preferentially hydrolyzes
phosphatidylcholine (PC) in fat-overladen LDL to re-
lease unsaturated fatty acids (e.g., oleate and linoleate)
in vivo [18]. As such, the increased LDL lipid levels in
Pla2g5−/− mice could impact on adipocyte hypertrophy
and the fatty liver. Furthermore, in accordance with the
alterations in LDL phospholipids, the levels of free ole-
ate and linoleate are lower in the adipose tissue of HFD-
fed Pla2g5−/− mice than in that of WT mice. These un-
saturated fatty acids released by sPLA2-V dampen the
M1 macrophage polarization by saturated fatty acids
(e.g., palmitate) likely through the attenuation of ER
stress. This mechanism fits with the view that sPLA2-V
has an apparent, even if not strict, substrate preference
for PC bearing a fatty acid with a low degree of
unsaturation.
It remains obscure whether the sPLA2-V action would
depend on the production of ω6 arachidonic acid-derived
eicosanoids (e.g., prostaglandins and leukotrienes) or ω3
polyunsaturated fatty acid (e.g., eicosapentaenoic acid and
docosahexaenoic acid)-derived pro-resolving lipid media-
tors (e.g., resolvins and protectins), since the adipose tis-
sue levels of these fatty acid metabolites were not affected
by Pla2g5 deficiency. Rather, sPLA2-V contributes to
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tween saturated (detrimental) and unsaturated (beneficial)
fatty acids, in adipose tissue microenvironments, providing
a novel insight into the sPLA2 action beyond lipid media-
tors. Together, these results reveal a functional link between
lipoprotein metabolism and anti-inflammation for this par-
ticular sPLA2 and provide a rationale for the long-standing
issue of the physiological importance of lipoprotein hy-
drolysis by this extracellular enzyme family (Fig. 2).
Another intriguing feature of sPLA2-V is that it is a
“Th2/M2-prone sPLA2,” allowing a shift in the immune
balance toward the Th2/M2 status. Apart from the crucial
role of adipocyte- rather than macrophage-derived sPLA2-
V in obesity, the Pla2g5 expression in macrophages is
markedly induced by the M2-skewing Th2 cytokines IL-4
and IL-13 and the Pla2g5 ablation decreases the Th2-
mediated immune responses [18, 31]. In vitro, exogenous
sPLA2-V is capable of facilitating the M2 polarization of
macrophages probably through augmenting the prostaglan-
din E2 production [18]. Furthermore, in human macro-
phages, sPLA2-V induced by IL-4 promotes phagocytosis
through the production of lysophosphatidylethanolamine
[32]. Given the increased incidence of metabolic disorders
resulting from the genetic ablation of Th2 or M2 inducers
(e.g., Il4, Il13, Il33, Stat6, or Pparg) [33], the decreased
whole-body Th2/M2 status resulting from Pla2g5 defi-
ciency may also contribute to the exacerbation of obesity-
associated inflammation. This notion also accords with the
observations that Pla2g5−/− mice are protected from
asthma (Th2 dependent) [31], while suffering from more
severe fungal infection (Th1 dependent) or arthritis (Th17
dependent) [10, 34], where the Th2 immunity counteractsFig. 2 Metabolic regulation by “metabolic sPLA2s.” During obesity, two sPL
hydrolyzes PE and PS in lipoproteins (VLDL, LDL, and HDL) and facilitates fat a
release oleate and linoleate, which counteracts the palmitate-induced M1 pol
inflammation [18]the Th1/Th17-based inflammations. Thus, the fact that
sPLA2-V acts as a Th2/M2-prone sPLA2 can account for
the pro- versus anti-inflammatory actions of this enzyme in
distinct immunopathological settings (Fig. 3).
Notably, in humans, Pla2g5 gene polymorphisms correl-
ate with the LDL levels in subjects with type 2 diabetes or
obesity [35, 36]. The in vitro sPLA2-V susceptibility of LDL
from patients with type 2 diabetes is greater than that of
LDL from healthy controls [37]. Moreover, the Pla2g5 ex-
pression in the human visceral adipose tissue inversely cor-
relates with LDL plasma levels [18]. These results imply a
human relevance for the metabolic role of sPLA2-V.
sPLA2-IIE, another “metabolic sPLA2”
We also found that sPLA2-IIE, which remained a func-
tionally orphan sPLA2 for more than a decade, acts as an-
other “metabolic” sPLA2 that is induced in hypertrophic
adipocytes [18]. An adipogenic stimulus is sufficient for
induction of sPLA2-IIE in adipocytes. Pla2g2e
−/− mice are
modestly protected from diet-induced obesity, hepatic
steatosis, and hyperlipidemia. In contrast to sPLA2-V,
which hydrolyzes PC in LDL to selectively release oleate
and linoleate (see above), sPLA2-IIE preferentially hydro-
lyzes minor lipoprotein phospholipids, phosphatidylserine
(PS), and phosphatidylethanolamine (PE), with no appar-
ent fatty acid selectivity. As such, sPLA2-IIE alters the
lipid composition of lipoproteins, thereby moderately af-
fecting the lipid accumulation in the adipose tissue and
liver.
Although the molecular mechanism that links lipopro-
tein PS/PE hydrolysis with obesity still remains unclear,
this study revealed for the first time the importance ofA2s (IIE and V) are induced in hypertrophic adipocytes. sPLA2-IIE
ccumulation into the peripheral tissues. sPLA2-V hydrolyzes PC in LDL to
arization of macrophages and thereby sequesters adipose tissue
Fig. 3 Immune balance regulation by sPLA2-V. sPLA2-V is induced in the M2 macrophages and Th2 cells by IL-4 or IL-13 and promotes Th2/M2-dominant
immunity such as asthma [31, 32]. Conversely, sPLA2-V plays protective roles in Th1- or Th17-type immune responses including obesity, infection, and
arthritis [10, 18, 34]
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regulation. As the increase of the negative charges in li-
poproteins by oxidative modification renders the parti-
cles smaller, the increase of the anionic phospholipids
(e.g., PS) in lipoproteins by the absence of sPLA2-IIE
may also afford a similar effect. Alternatively, lysopho-
sphatidylethanolamine or lysophosphatidylserine pro-
duced by sPLA2-IIE might have some metabolic effects,
a possibility that awaits future studies. Collectively, these
results underscore the physiological relevance of lipo-
protein hydrolysis by distinct sPLA2s and highlight the
importance of “metabolic sPLA2s” as the integrated reg-
ulators of metabolic responses (Fig. 2).
On the other hand, another study has recently re-
ported that Pla2g2e−/− mice accumulate more epididy-
mal fat as they age [38]. During adipogenesis, the
genetic deletion or siRNA knockdown of sPLA2-IIE in-
creases the triglyceride in adipocytes, while its overex-
pression or exogenous addition facilitates lipolysis.
Although the reason for the discrepancy between the
two studies is unclear, it might have arisen from different
experimental conditions (HFD versus chow diets or fe-
male versus male mice) in different animal facilities.
sPLA2-IB, a “digestive sPLA2”
Systemic lipid metabolism is often affected by the diges-
tion and absorption of dietary lipids in the GI tract.
sPLA2-IB is synthesized by pancreatic acinar cells, and
after secretion as a zymogen into pancreatic juice, an N-
terminal propeptide of the inactive zymogen is cleaved
by trypsin to yield an active enzyme in the duodenum.
The hydrolysis of PC by sPLA2-IB is greatly accelerated
in the presence of a low concentration of detergent such
as deoxycholate [39]. This property appears to be
physiologically important since the digestion of dietary
phospholipids by sPLA2-IB occurs in the presence of bile
acid in the GI tract.Pla2g1b−/− mice show resistance to obesity, lower
plasma insulin and leptin levels, and improved glucose
tolerance when fed a high-fat/carbohydrate diet [40].
These phenotypes of Pla2g1b−/− mice are most likely
due to a marked reduction in the hydrolysis of dietary
and biliary PC and thereby in the production and ab-
sorption of lysophosphatidylcholine (LPC) in the GI
tract. The increased intestinal absorption of LPC
promotes postprandial hyperglycemia by inhibiting the
glucose uptake by the liver and muscle, and accordingly,
the absence of sPLA2-IB reduces the postprandial LPC
levels, leading to improved insulin sensitivity and hepatic
fatty acid oxidation [41, 42]. It is noteworthy that
Pla2g1b−/− mice on a Ldlr−/− background are protected
from body weight gain and atherosclerosis in response
to a hypercaloric diet [43] and that the oral administration
of the sPLA2 inhibitor methyl indoxam along with a dia-
betogenic diet effectively suppresses diet-induced obesity
and diabetes in mice likely through the prevention of the
intestinal digestion of dietary and biliary PC by sPLA2-IB
[44]. In further support of these observations, pancreatic
acinar cell-specific Pla2g1b-transgenic mice develop more
severe obesity and insulin resistance [45]. These results
suggest that the inhibition of sPLA2-IB, a “digestive
sPLA2,” may be an effective oral therapeutic option for the
treatment of diet-induced obesity and diabetes.
Complex and enigmatic roles of sPLA2-X in metabolism
Lastly, we briefly summarize the possible metabolic roles of
sPLA2-X, although details remain uncertain because of the
fact that conflicting results have been obtained. Like
sPLA2-IB, sPLA2-X also has an N-terminal propeptide, and
its proteolytic removal leads to the full activation of the en-
zyme. A series of studies have provided some insights into
the functional link of sPLA2-X-released polyunsaturated
fatty acids to lipid-sensing nuclear receptor signaling.
Macrophages from Pla2g10−/− mice show an increased
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and ABCG1, and this effect appears to be dependent on
the suppression of the liver X receptor (LXR) by sPLA2-X-
released polyunsaturated fatty acids [46]. Moreover, the in-
creased cholesterol content of the lipid rafts in Pla2g10−/−
macrophages leads to significant reduction of endotoxin-
induced inflammation [47]. The sPLA2-X-dependent sup-
pression of LXR can also occur in the adipose tissue, where
Pla2g10 deficiency facilitates adipogenesis and obesity [48],
and in the adrenal glands, where its deficiency promotes
corticosteroidogenesis through the activation of steroido-
genic acute regulatory protein [49]. In the latter case, pro-
sPLA2-X is proteolytically processed to a mature, active
form by the protein convertases furin and PCSK6, which
are induced by the adrenocorticotropic hormone, in adrenal
cells [50]. However, as far as we have been able to examine,
the Pla2g10 expression in mouse macrophages and the adi-
pose tissue is very low, arguing against the above observa-
tions. Rather, we prefer the idea that sPLA2-X might be
expressed in a limited subset of these cells or supplied from
proximal or distal cells in a paracrine manner.
On the other hand, we have shown that sPLA2-X is
expressed abundantly in GI-lining cells and participates
in phospholipid digestion [19]. Accordingly, Pla2g10−/−
mice display a reduced age-associated adiposity and im-
proved insulin sensitivity in the skeletal muscle, likely
through a mechanism reminiscent of that in Pla2g1b−/−
mice. Thus, the two “digestive sPLA2s” (IB and X) may
spatiotemporally control the hydrolysis of dietary and
biliary phospholipids and thereby the absorption of their
hydrolytic products, depending on the quantity and
quality of the dietary and biliary fat input. As in the case
of Pla2g2e−/− mice (see above), the opposite phenotypes
of Pla2g10−/− mice observed in different studies might
have been due to differences in the experimental models
or housing conditions employed, and further studies will
be necessary to clarify more definitively the roles and
mechanistic actions of sPLA2-X in metabolism.
It has been recently reported that the glucose-
stimulated insulin secretion by islet β cells is augmented
in Pla2g10−/− mice, underscoring a novel metabolic role of
sPLA2-X [51]. Mechanistically, sPLA2-X negatively regu-
lates insulin secretion by augmenting the cyclooxygenase-
2-dependent prostaglandin E2 production. In this
scenario, targeting sPLA2-X may be an effective
therapeutic option for enhancing β cell function in
the treatment of diabetes.
Conclusions
It is now obvious that at least four sPLA2s are involved
in metabolic regulation through distinct mechanisms, as
summarized below. sPLA2-V is induced in hypertrophic
adipocytes by obesity-associated ER stress and hydro-
lyzes PC in hyperlipidemic LDL to facilitate the skewingof macrophages from M1 to M2 subsets, thereby confer-
ring protection from adipose tissue inflammation, insulin
resistance, obesity, hepatic steatosis, and hyperlipidemia.
The saturated fatty acids supplied abundantly from adipo-
cytes trigger the M1 polarization of macrophages, which
is counterregulated by the sPLA2-V-driven unsaturated
fatty acids from LDL. sPLA2-IIE is induced in adipocytes
in accordance with adipogenesis and hydrolyzes PE and
PS in lipoproteins, eventually promoting fat storage in the
adipose tissue and liver. sPLA2-IB, a pancreatic sPLA2 that
is secreted into the GI lumen, hydrolyzes dietary and bil-
iary phospholipids to promote lipid digestion and absorp-
tion, which is associated with obesity and hepatic insulin
resistance. sPLA2-X variably affects metabolism possibly
through the production of polyunsaturated fatty acids that
modify the LXR signaling in the adipose tissue, through
the digestion of the dietary and biliary phospholipids in
the gut, or through the generation of prostaglandin E2 that
suppresses insulin secretion in the pancreatic islet. In
addition, sPLA2-IIA is abundantly expressed in the human
and rat adipose tissues in obesity and the pharmacological
inhibition of this isoform attenuates the adipose tissue in-
flammation in rats [18, 52]. It remains possible that other
sPLA2 isoforms may also participate in metabolic regula-
tion, and this issue is now under investigation. Together,
these studies have brought about a paradigm shift toward a
better understanding of the biological roles of this extracel-
lular lipolytic enzyme family as coordinators of metabolism.
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